Dapagliflozin Is A New Drug For The Treatment Of Type Two Diabetes

Dapagliflozin Is A New Drug For The Treatment Of Type Two Diabetes.
A unfamiliar drug, the oldest in its class, gives added blood sugar hold sway over to man with type 2 diabetes who are already taking the glucose-lowering medication metformin. The experimental agent, dapagliflozin, which also helped patients waste weight, is novel in that it does not work undeviatingly on the body's insulin mechanisms, according to a study appearing in the June 26 affair of The Lancet and slated for presentation at the annual gathering of the American Diabetes Association (ADA) in Orlando 4 rx day. "It will presumably be used as an add-on therapy," said study prima donna author Clifford Bailey, a chemical pathologist and professor of clinical sphere at Aston University in Birmingham, UK "If you don't perfectly get to target with the first therapy tried , this proposition would offer you an opportunity hopefully to maintain improved control".

Bailey, who could not foresee if or when the drug might get final approval from drug regulatory authorities, also aciform out that dapagliflozin is flexible, meaning it can be used with various other treatments and at more or less any place in the disease. "It's a good add-on," agreed Dr Stanley Mirsky, confederate clinical professor of metabolic diseases at Mount Sinai Medical Center in New York City skin care. "is it a miracle drug? no. It may movement a tight role".

The study was funded by Bristol-Myers Squibb and AstraZeneca, which are developing dapagliflozin together. Dapagliflozin mechanism by thought-provoking the kidneys to eliminate more glucose from the body via urine. In this swot of 534 adult patients with type 2 diabetes who were already taking metformin, the highest amount of dapagliflozin (10 milligrams daily) was associated with a 0,84 percent abate in HbA1c levels.

HbA1c is a weigh of blood sugar control over time. Participants taking 5 mg of the stupefy saw a 0,70 percent decrease in HbA1c levels, while those taking 2.5 mg had a 0,67 percent decrease. In the placebo group, the wane in HbA1c was 0,3 percent, the learning found.